



HEIDELBERG UNIVERSITY HOSPITAL



PRELIMINARY PROGRAM

9TH HEIDELBERG MYELOMA WORKSHOP

Congress venue:

Medical University Hospital Heidelberg

Lecture Hall | Im Neuenheimer Feld 410 | 69120 Heidelberg

FRIDAY, APRIL 21ST, 2023

SATURDAY, APRIL 22ND, 2023



NCT

NATIONAL CENTER
FOR TUMOR DISEASES
HEIDELBERG



DEAR COLLEAGUES,

Welcome to the 9th Heidelberg Myeloma Workshop.

This biennial meeting continues to focus on new developments in multiple myeloma and a panel of internationally renowned experts discuss the range of current therapeutic approaches.

Recent years have seen myeloma patients benefit from more refined diagnostic criteria and a wider range of treatment options. Both the earlier initiation of treatment and a greater appreciation of the importance of targeting sustained deep remissions offer new opportunities to further extend patient survival. Most importantly, novel agents have been approved and immunotherapeutic approaches, like T-cell engagers or CAR-T cells, are about to transform the treatment landscape for our patients.

Myeloma is, like any cancer, a range of diseases. We are however, now able to make use of clinical, chromosomal and molecular markers to accurately identify robust prognostic groups. Risk-adapted treatment strategies as well as personalized therapies are now being intensively explored and first results show great promise.

We hope that this program will be of interest to you and look forward to welcoming you to Heidelberg.

The language of the meeting is English.

Sincerely,



Prof. Dr. Marc S. Raab



Dr. rer. nat. Niels Weinhold

FRIDAY, APRIL 21ST, 2023

12.00 – 12.45 p.m. Registration and Get Together

12.45 – 1.00 p.m.

Introduction and Opening Remarks

Marc S. Raab, Heidelberg

Hartmut Goldschmidt, Heidelberg

Carsten Müller-Tidow, Heidelberg

Ingo Autenrieth, Heidelberg

Niels Weinhold, Heidelberg

SESSION I 1.00 – 2.00 p.m.

Evolution & Treatment of SMM

Chair: *Patrick Hayden, Dublin*

Elias Mai, Heidelberg

1.00 – 1.15 p.m.

The evolutionary pathways leading to multiple myeloma

Brian Walker, Indianapolis

1.15 – 1.30 p.m.

Treatment of high-risk smoldering: pros

Maria Victoria Mateos, Salamanca

1.30 – 1.45 p.m.

Treatment of high-risk smoldering: cons

Sagar Lonial, Atlanta

1.45 – 2.00 p.m.

Discussion

SESSION II 2.00 – 3.00 p.m.

Minimally Invasive Response Assessment

Chair: *Stefan Delorme, Heidelberg*

2.00 – 2.15 p.m.

Using PET for response assessment (Update)

Carolina Schinke, Arkansas

2.15 – 2.30 p.m.

Mass spectrometry

Elias Mai, Heidelberg

2.30 – 2.45 p.m.

Using MRI for response assessment (Update)

Jens Hillengass, Buffalo

2.45 – 3.00 p.m.

Discussion

3.00 – 3.30 p.m.

Coffee Break

SESSION III

3.30 – 4.45 p.m.

Current Concepts for Newly Diagnosed Myeloma

Chair: Hans Salwender, Hamburg

Sandra Sauer, Heidelberg

3.30 – 3.45 p.m.

First-line transplant eligible (Update)

Hartmut Goldschmidt, Heidelberg

3.45 – 4.00 p.m.

CONCEPT trial (Update)

Katja Weisel, Hamburg

4.00 – 4.15 p.m.

MASTER trial (Update)

Ola Landgren, Miami

4.15 – 4.30 p.m.

First-line transplant ineligible

Thierry Facon, Lille

4.30 – 4.45 p.m.

Discussion

4.45 – 5.00 p.m.

Coffee Break

5.00 – 5.30 p.m.

Key Note Lecture

Novel Agents Beyond Immunotherapy

Shaji Kumar, Rochester

SESSION IV 5.30 – 6.45 p.m.

Curing Myeloma

*Chair: Monika Engelhardt, Freiburg
Stefanie Huhn, Heidelberg*

5.30 – 5.45 p.m.

Risk-stratified treatment approaches

Martin Kaiser, London

5.45 – 6.00 p.m.

The evolutionary pathways of myeloma cells in deep-responding patients

Leo Rasche, Würzburg

6.00 – 6.15 p.m.

Treatment decisions based on MRD data: pros

Bruno Paiva, Pamplona

6.15 – 6.30 p.m.

Treatment decisions based on MRD data: cons

Martin Kaiser, London

6.30 – 6.45 p.m.

Discussion

6.45 – 7.00 p.m.

Short Summary and End of Day 1

Marc-Steffen Raab, Heidelberg

SATURDAY, APRIL 22ND, 2023

9.00 – 9.30 a.m. Get Together

9.30 – 10.00 a.m.

Key Note Lecture

What is the Next Big Thing in Myeloma Therapy?

Kenneth C. Anderson, Boston

SESSION I

10.00 – 11.00 a.m.

Myeloma Genomics

Chair: *Leo Rasche, Würzburg*

Niels Weinhold, Heidelberg

10.00 – 10.15 a.m.

Complex structural aberrations and impact on outcome

Gareth Morgan, New York

10.15 – 10.30 a.m.

Mutational signatures

Francesco Maura, Miami

10.30 – 10.45 a.m.

Impact of genomic complexity on the transcriptome of multiple myeloma

Niccolo Bolli, Milano

10.45 – 11.00 a.m.

Discussion

11.00 – 11.15 p.m.

Coffee Break

SESSION II

11.15 – 12.30 a.m.

Immunotherapy I

Chair: *Peter Dreger, Heidelberg*

11.15 – 11.30 a.m.

CD38 Antibody treatment

Philippe Moreau, Nantes

11.30 – 11.45 a.m.

Current CAR-T cells - Clinical overview

Paula Rodriguez Otero, Pamplona

11.45 – 12.00 a.m.

CAR real world data

Christoph Scheid, Köln

12.00 – 12.15 p.m.

Role of BM microenvironment in MM progression and response to CAR-T therapies in Myeloma

Paola Neri, Calgary

12.15 – 12.30 p.m.

Discussion

12.30 – 1.30 p.m.

Lunch

SESSION III

1.30 – 2.45 p.m.

Immunotherapy II

Chair: Markus Munder, Mainz

Leif Bergsagel, Scottsdale

1.30 – 1.45 p.m.

Novel CAR-T cell constructs

Hermann Einsele, Würzburg

1.45 – 2.00 p.m.

Antibody-drug conjugates

Suzanne Trudel, Toronto

2.00 – 2.15 p.m.

Immune microenvironment and stroma cells

Tom Cupedo, Rotterdam

2.15 – 2.30 p.m.

T-cell engagers, a clinical update

Nizar Bahlis, Calgary

2.30 – 2.45 p.m.

Discussion

2.45 – 3.00 p.m.

Coffee Break

SESSION IV **3.00 – 4.30 p.m.**

Novel Resistance Mechanisms

*Chair: Christoph Driessen, St. Gallen
 Florian Bassermann, München*

3.00 – 3.15 p.m.

PI and IMiD Resistance

Martin Kortüm, Würzburg

3.15 – 3.30 p.m.

Combination of SOC and bispecific antibodies: lessons from an IMiD-responsive immunocompetent mouse model

Marta Chesi, Scottsdale

3.30 – 3.45 p.m.

Proteomic studies to uncover non-genetic resistance mechanisms in myeloma

Jan Krönke, Berlin

3.45 – 4.00 p.m.

Immunotherapeutic vulnerabilities

Jens Lohr, Boston

4.00 – 4.15 p.m.

Immunological mechanisms and determinants of response to T cell-redirecting therapies

Mirco Friedrich, Cambridge

4.15 – 4.30 p.m.

Discussion

4.30 – 4.45 p.m.

Summary and Closing of the Workshop

Marc-Steffen Raab, Heidelberg

We would like to thank all our sponsors for supporting the 9th Heidelberg Myeloma Workshop:

abbvie

AbbVie Deutschland GmbH & Co. KG
65189 Wiesbaden – 25.000€

AMGEN

Onkologie

Amgen GmbH
80992 München – 25.000€

 Bristol Myers Squibb

Bristol-Myers Squibb GmbH & Co. KGaA
80636 München – 50.000€



GlaxoSmithKline GmbH & Co. KG,
81675 München – 25.000€

Janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

Janssen-Cilag GmbH
41470 Neuss – 40.000€

 oncopeptides

Oncopeptides GmbH
81541 München – 3.000€

 **Pfizer**

Pfizer Pharma GmbH
10785 Berlin – 10.000€

SANOFI GENZYME

Sanofi-Aventis Deutschland GmbH
65926 Frankfurt – 25.000€

sebia

Sebia Labordiagnostische Systeme GmbH
55129 Mainz – 2.000€

Stemline[®]
A Menarini Group Company

Stemline Therapeutics Switzerland GmbH
6300 Zug (CH) – 10.000€



Takeda Pharma Vertrieb GmbH & Co. KG
10783 Berlin – 2.500€

Binding Site

The Binding Site GmbH
68723 Schwetzingen – 2.000€

Sponsors will receive the opportunity to advertise their products before and/or after the event.

ORGANISATION AND CONGRESS VENUE

9TH HEIDELBERG MYELOMA WORKSHOP

University Hospital Heidelberg
Department of Medicine V and
National Center for Tumor Diseases (NCT)
Multiple Myeloma Section
Lecture Hall of the Medical Hospital Heidelberg
Im Neuenheimer Feld 410 | 69120 Heidelberg

CONTACT AND REGISTRATION

Laura Schaaf

Phone: **+49 6221 56-8009**

E-Mail: **laura.schaaf@med.uni-heidelberg.de**

Register online at: **www.myelomaworkshop.de**

WWW.KLINIKUM.UNI-HEIDELBERG.DE
WWW.NCT-HEIDELBERG.DE